Anti-diabetic drug market has been potentially growing in India. As several drugs have been launched by various Indian pharmaceutical companies, Zydus Cadila has made a breakthrough in the diabetes drug market by launching its new drug at the most affordable cost.
Cadila has offered its drug Tenglyn, the generic version of oral anti-diabetic drug gliptins at a price of Rs. 7 per tablet in India. Gliptins have been ruling the diabetes market with its potential to induce insulin in the blood. Several pharma companies like Glenmark, Ajanta are already selling the same drug at a cost of Rs. 20 per tablet.
‘The new anti-diabetic drug, Tenglyn offered at a price of rs.7 per tablet will be a boon for 60 million diabetic patients in India.’
Advertisement"With Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost," said Sharvil Patel, Deputy Managing Director, Zydus Cadila.
Therefore, this new launch of the same drug at a cost of rs.7 will help 60 million diabetic patients economically. The cost-effective drug will also be made easily accessible all over the country. The price of Zydus is said to be one sixth of all other pharmaceutical companies.